Results 251 to 260 of about 29,662,154 (279)
Some of the next articles are maybe not open access.
A safety update on sodium glucose co‐transporter 2 inhibitors
Diabetes, Obesity and Metabolism, 2019Sodium glucose co‐transporter 2 inhibitors (SGLT2is) are the first class of glucose lowering agent to be shown to reduce cardiovascular events. They are generally well tolerated with infrequent serious adverse events. The most frequent side effect is genital mycotic infections with candida species that are usually mild to moderate in severity, easily ...
openaire +2 more sources
Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors
Drug and Therapeutics Bulletin, 2023After initially being licensed as treatment for diabetes, the range of indications for sodium-glucose co-transporter 2 (SGLT2) inhibitors has expanded to include chronic heart failure and chronic kidney disease. This article provides an overview of some of the evidence that supports the use of SGLT2 inhibitors in the management of chronic heart failure
openaire +2 more sources
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
European Journal of Pharmacology, 2021Nonalcoholic fatty liver disease (NAFLD) is considered the most prevalent chronic hepatic disease, as it has been estimated that one of four individuals in the general population has been affected by NAFLD. The evolution of the referred entity, which includes nonalcoholic steatohepatitis (NASH) and hepatic fibrosis, may have crucial and even fatal ...
Evangelia S. Makri +2 more
openaire +2 more sources
Sodium-glucose co-transporter 2 inhibitors: evidence and place in therapy
Expert Review of Endocrinology & Metabolism, 2015Type 2 diabetes effects millions of people yet remains difficult to treat with oral pharmacotherapy. Metformin is the first line recommended therapy, and current guidelines suggest individualized therapy for second line selection. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the newest class of agents in treating type 2 diabetes via an ...
Molly G, Minze +4 more
openaire +2 more sources
Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering
Current Drug Targets, 2018Diabetes is an important cause of morbidity and mortality worldwide. Management of blood glucose is critical for diabetic patients since diabetes carries a risk for many diseases and disorders. Although there are several antidiabetic agents in the markets for a long time, some of the agents have dose-limiting side effects, such as hypoglycemia and ...
Ceylan, Asli F., Ren, Sidney Y.
openaire +3 more sources
[Sodium-glucose co-transporter 2 inhibitor for diabetes?].
Nederlands tijdschrift voor geneeskunde, 2016Following initial expectations, raised by the results of the United Kingdom Prospective Diabetes Study, intervention studies aimed at tight glucose control did not reduce cardiovascular disease. The EMPA-REG OUTCOME, an empagliflozin intervention study in over 7,000 patients with type 2 diabetes mellitus and a history of cardiovascular disease, for the
openaire +1 more source
A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
Cell Metabolism, 2021Hiddo J L Heerspink, Taha Sen
exaly
Comment on Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure
The American Journal of Cardiology, 2020Erkan Cure, Medine Cumhur Cure
openaire +2 more sources